PsyMuKB

PPI network (data source: BioGrid)

A gene is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the mean normalized expression(base 2 log of (TPM+1)) +1 in all brain tissue from GTEx v7 or BrainSpan data.

A protein is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the normalized expression (base 10 log of iBAQ intensity) ≥0.5 in at least one brain tissue from ProteomicsDB data. Otherwise, a gene or protein is determined as either with below-cutoff expressions or no available data.

	The queried gene/protein
	The interacting partner is expressed at mRNA-level
	The interacting partner is expressed at protein-level
	The interacting partner is expressed at both mRNA and protein level
	The interacting partner is with either below-cutoff expressions or no expression data at both mRNA and protein level
	The interacting partner is hit by coding DNMs
	Physical interaction between queried gene/protein and its partner
	Physical interaction between two interacting partners

Symbol A	GeneA coding DNM count	Symbol B	GeneB coding DNM count	Interaction detection method	Publication	Evidence
YES1	1	FYN	1	affinity chromatography technology, affinity chromatography technology	Piedra J (2003), Huttlin EL (2017)	2
KIRREL1	0	NPHS1	2	affinity chromatography technology, affinity chromatography technology	Liu G (2003), Gerke P (2003)	2
NPHS1	2	YES1	1	affinity chromatography technology	Verma R (2003)	1
MAP2K3	1	MAP2K6	2	genetic interference, affinity chromatography technology, imaging technique, affinity chromatography technology, fluorescent resonance energy transfe	Huber TB (2001), Huttlin EL (2015), Chen TC (2014), Huttlin EL (2017), Ivanov AA (2017)	5
NPHS1	2	NPHS1	2	affinity chromatography technology	Gerke P (2003)	1
NPHS2	1	SH3KBP1	1	affinity chromatography technology, affinity chromatography technology	Tossidou I (2010), Tossidou I (2010)	2
NPHS1	2	MAP2K6	2	genetic interference	Huber TB (2001)	1
MAP2K6	2	MAP2K4	3	enzymatic study	Takekawa M (2005)	1
NPHS1	2	SH3KBP1	1	affinity chromatography technology, affinity chromatography technology, imaging technique	Tossidou I (2010), Tossidou I (2010), Tossidou I (2010)	3
NPHS1	2	MAP2K3	1	genetic interference	Huber TB (2001)	1
NPHS2	1	NPHS1	2	affinity chromatography technology, pull down	Schwarz K (2001), Schwarz K (2001)	2
NPHS1	2	CANX	4	affinity chromatography technology, affinity chromatography technology, imaging technique	Drozdova T (2013), Drozdova T (2013), Drozdova T (2013)	3
SH3KBP1	1	CD2AP	0	affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Tossidou I (2010), Gaidos G (2007), Huttlin EL (2017)	3
FYN	1	SH3KBP1	1	affinity chromatography technology	Narita T (2005)	1
ALB	1	NPHS1	2	affinity chromatography technology	Zhou M (2004)	1
NPHS1	2	CD2AP	0	affinity chromatography technology	Tossidou I (2010)	1
NPHS2	1	CD2AP	0	affinity chromatography technology, pull down, affinity chromatography technology	Schwarz K (2001), Schwarz K (2001), Tossidou I (2010)	3
NPHS1	2	IQGAP1	1	affinity chromatography technology	Liu Y (2015)	1
NPHS1	2	MAP2K4	3	genetic interference	Huber TB (2001)	1
NPHS1	2	FYN	1	affinity chromatography technology, affinity chromatography technology, pull down, affinity chromatography technology, enzymatic study	Lahdenperae J (2003), Verma R (2003), Verma R (2003), Verma R (2003), Verma R (2003)	5